Diaverum announces the appointment of Krisja Vermeylen to its Board of Directors, and as Chair of the Remuneration Committee.
Krisja brings more than 30 years of experience in healthcare and big pharma, the last 20 spent in various management positions at Novo Nordisk and prior to that, several years at Pharmacia (today Pfizer). Ms. Vermeylen is a pharmacist by training and holds a master's degree in pharmaceutical sciences from the University of Antwerp (UIA, RUCA), Belgium.
“Krisja Vermeylen is a very experienced board member, particularly within the international healthcare sector. We are confident that she will add great value to the board, and that Diaverum will benefit from her insights, judgment and counsel”, says Kenneth Bengtsson, Chairman Diaverum.
She holds more than 20 years of experience of various board assignments, and is currently chairman of the Spencer Stuart Brussels Advisory Board and an Independent Director of Morphosys AG.
“I am really looking forward to supporting Diaverum in its ambition to deliver high quality renal care and as such improving the lives of many patients and their families”, says Krisja Vermeylen about her new assignment.